Kamada secures $20M from Hercules Capital
Kamada, an Israel-based biopharmaceutical company, has signed a $20.0 million financing agreement with the USA's Hercules Technology Growth Capital under venture lending terms. The agreement is aimed at diversifying the company's financing resources and to further finance its strategic plans over the forthcoming years.
HTGC is a publicly-traded specialty finance company focused on providing debt and equity growth capital to technology and life science companies at all stages of development. Kamada is one of a select group of Israeli companies to join forces with Hercules following the latter's June 2007 announcement of its intent to provide the Israeli market with financing opportunities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze